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Abstract The effects of 3,3’,5 triiodo+thyronine (L-T3) on the 
constitutive levels of hepatic mRNA encoding two UDP-glucu- 
ronosyltransferase (UGT) isoforms implicated in the glucu- 
ronidation of planar phenolic substrates (UGT1*06) and bilirubin 
(UGTl*O) were investigated in rat liver. The amount of UGT 
mRNA was quantitated by reverse transcription and amplifica- 
tion methods (RT-PCR). Treatment with L-T3 significantly in- 
creased UGT1*06 and decreased UGTl*O mRNA levels by 41% 
and 54%, respectively. The opposite situation was observed in 
thyroidectomised animals. A good relationship observed between 
UGT activity toward 4-nitrophenol and bilirubin and mRNA lev- 
els emphasizes the key role played by the thyroid hormone L-T3 
on UGT expression. 
Key words: UDP-glucuronosyltransferase; Liver (rat); 
Gene expression; 3,3’,5 Triiodo-r.-thyronine; Bilirubin 
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1. Introduction 
UDP-glucuronosyltransferase (UGTs, EC 2.4.1.17), which 
are encoded by a superfamily of genes, catalyze the conjugation 
of glucuronic acid to a large variety of structurally unrelated 
compounds with hydroxyl-, carboxyl-, amine or sulfhydryl 
groups [l]. Drugs or endogenous compounds that are impor- 
tant for cell differentiation and growth (e.g. steroid and thyroid 
hormones, fatty acids, retinoic acid) are substrates of these 
enzymes [2,3]. Thyroid hormones are both substrates and in- 
ducers of UGTs. They are glucuronidated on the phenolic or 
carboxyl group and excreted as inactive metabolites into bile 
[4]. On the other hand, we and others demonstrated that thy- 
roid hormones differentially affected the glucuronidation by rat 
liver microsomes of various substrates supported by separate 
UGTs [5,6]. Interestingly, we previously reported, using thy- 
roidectomised animals, that treatment with L-T3 and analog 
compounds increased, in a dose-dependent fashion, the glucu- 
ronidation of 4-nitrophenol, whereas that of bilirubin and the 
monoterpenoid nopol were decreased and unchanged, respec- 
tively. These opposite changes in enzyme activities were ob- 
*Corresponding author. Fax: (33) 80 39 33 00. 
Abbreviations: UGT, UDP-glucuronosyltransferase; L-T3, 3,3’,5-tri- 
iodo-L-thyronine; RT-PCR, reverse transcription-polymerase chain re- 
action; 3-MC. 3-methylcholanthrene. 
served in detergent-activated and in native microsomal prepa- 
rations, without any variation of the lipid fluidity of the micro- 
somal membranes [7]. Therefore a modification of the expres- 
sion of the individual UGT isoforms upon thyroid hormone 
treatment, rather than variations of enzyme latency, was sus- 
pected. The aim of the present study was to explain the modu- 
lation, in opposite ways, of the activity of two UGT isoforms 
implicated in the glucuronidation of 4nitrophenol (UGT 1*06) 
and bilirubin (UGTl *0) by thyroid hormones. These enzymes 
are encoded by two members of family 1 of the UGT gene 
superfamily. The asterisk indicates that these isoforms derive 
by alternative splicing from a primary transcript common to 
several isoforms encoded by the UGTI locus. The constitutive 
levels of hepatic mRNA encoding the two enzymes were meas- 
ured by RT-PCR method using highly specific primers which 
hybridize two corresponding cDNAs. Their expression varia- 
tions were followed in hypo-, normo- and hyperthyroid ani- 
mals. The inducing effect of 3-methylcholanthrene and that of 
the peroxisome proliferator, ciprofibrate, that are known to 
stimulate the glucuronidation of 4nitrophenol and bilirubin, 
respectively [8,9], were also monitored as positive controls. Our 
results clearly show that the opposite changes observed in glu- 
curonidation of 4nitrophenol and bilirubin could be explained 
by variations of the levels of the corresponding mRNAs. 
2. Materials and methods 
4-Nitrophenol, bilirubin and detergents for enzyme activation, Tri- 
ton X-100 and digitonin were purchased from Merck (Darmstadt, Ger- 
many). Ciprofibrate [2-(4-(2-2dichlorocyclopropyl)phenoxyl-2methyl- 
propionic acid)] was a gift from Sterling-Winthrop (Dijon, France). 
3,3’,5 Triiodo-L-thyronine (L-T3), goat anti-rabbit IgG, silver stain kit 
and 3-methylcholanthrene (3-MC) were purchased from Sigma Chem- 
ical Co. (St. Louis, MO). Restriction enzymes, 5-bromo-4-chloro-3- 
indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) were ob- 
tained from GIBCO BRL (Eragny, France). Moloney murine leukemia 
virus (MMLV) reverse transcriptase, ribonuclease inhibitor, random 
primers, DNA size standards (phi X 174 digested with HinfI) were 
purchased from Promega Corporation (Lyon, France). Taq polym- 
erase, dNTP were from Bioprobe Systems (Montreuil-sous-Bois, 
France). All other chemicals were reagent grade. The oligonucleotide 
primers were synthesized using an Applied Biosystem Model 394-08 
DNA synthesizer (Bioprobe Systems), and PCR reactions were per- 
formed in a thermal controller incubator (Models PTC-150-16 & -25 
DNA). The gels were scanned with an Ultroscan XL enhanced laser 
densitometer from LKB (Bromma, Sweden). 
2.1. Treatment of rats and UGT assays 
Male Wistar rats from a SPF husbandry (Iffa Credo, St. Germain 
I’Arbresle, France), were used. Except for a control group, the thyroid 
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gland was surgically removed when the animals weighed 80 g. Each 
group of rats was composed of eight animals. A control and a group 
of thyroidectomised rats did not receive any compound. One group of 
rats was treated intraperitoneally with L-T3 dissolved in 0.9% NaCl at 
a dose of 50 &kg/day for eight days. The other groups were treated 
with ciprofibrate (2 mg/kg/day) by gastric intubation for five days or 
with 3-MC by one single intraperitoneal injection of the compound 
dissolved in corn oil and administered 48 h before killing at a dose of 
80 mg/kg body weight. Rats were killed by decapitation 16 h after the 
last injection of L-T3 or ciprofibrate. The liver of each rat was removed, 
weighed and perfused with an ice cold 0.154 M KC1 solution. A part 
of the liver (200 mg) was collected from each rat, immediately frozen 
in liquid nitrogen and stored at -70°C for RNA extraction. Liver 
microsomes preparation, protein concentration and UGT activity to- 
wards bilirubin and 4-nitrophenol were performed as previously re- 
ported [7]. 
sequences recorded in data banks. Absence of genomic DNA contam- 
ination was verified by using a control tube supplemented with 10 pg 
of RNase. Measurement of mRNA encoding /l-actin was simultane- 
ously performed using two specific primers, according to Nude1 et al. 
[17], as internal standard (Table 1). A highly specific PCR would gen- 
erate only one product of the correct size that is the intended target 
sequence. Utilizing sequence information from data bank, the com- 
puter program Gene Joker was used to predict the restriction enzyme 
map for each expected PCR fragment. Specific PCR fragments were 
digested by various restriction enzymes for 1 h at 37°C to confirm the 
PCR products. 
2.2. Western blotting anulysis 
For quantitation purpose, 10 ~1 of the PCR reaction were sampled 
after 22 to 30 amplification cycles [18], and the co-amplified fragments 
were separated by electrophoresis on 5% polyacrylamide gel. The bands 
were visualized by silver staining and quantified by densitometry. To 
minimize errors, the scanning procedure was repeated three times, and 
the mean value for each area intensity was determined. The intra- and 
interassay coefficients of variation were 5% and 7.5%, respectively. 
The microsomal proteins were subjected to SDS-PAGE according to 
Laemmli [lo]. After transfer of proteins onto a Hybond C membrane, 
Western blot was performed by the method of Towbin et al. [l 11. UGT 
proteins were detected using two antibodies: a polyclonal antibody 
raised in rabbits against hepatic UGTs of rats treated by 3-MC, which 
recognizes, at least, four different UGT proteins, including 4-nitrophe- 
no1 and bilirubin UGTs [12]; a monospecific antibody raised in rabbits 
against the N-terminal end of the human liver UGT1*6, which is spe- 
cific for one UGT protein active toward planar phenols, only [13]. This 
antibody cross-reacts with the rat liver 4-nitrophenol UGT. Precipi- 
tated bands were detected by addition of a second antibody conjugated 
with rabbit alkaline phosphatase in the presence of BCIP and NBT. 
3. Results 
2.3. RNA unalysis 
Total RNA was extracted from hepatic tissues by the RNA QUICK 
II kit (Bioprobe Systems) as described by the supplier. Complementary 
DNA was synthesized from RNA samples by mixing 1 pug total RNA, 
100 pmol of random hexamer in the presence of 50 mM Tris-HC1 
buffer, (pH 8.3); 75 mM KCI; 3 mM MgCl,; 10 mM dithiothreitol; 200 
U of MMLV reverse transcriptase; 40 U of RNase inhibitor and 1 mM 
of each dNTP in a total volume of 20 ~1. Samples were incubated at 
37°C for 60 min and then diluted to 100 yl with sterile diethylpyrocar- 
bonate-treated H,O. The enzyme was inactivated by heating at 95°C 
for 5 min. A 10~1 aliquot was then used for subsequent PCR and added 
to a reaction mixture containing 20 mM Tris-HCl buffer (pH 8.5), 16 
mM (NH&SO,, 150 fig/ml bovine serum albumin, 0.2 mM of each 
dNTP, 50 pmol of each primer and 25 pmol of each internal standard 
primer in the same conditions. 2 U of Taq polymerase [14] and MgCl, 
at optimal concentration determined for each set of primers (1.5 mM 
and 0.5 mM for bilirubin UGT and 4-nitrophenol UGT, respectively). 
in a total volume of 50 ~1 were also added. Each mixture (50 ~1) was 
overlayed with 50 ~1 of mineral oil and incubated in a thermal cycler 
at 94°C for 5 min and immediately cycled 28 to 30 times through a 30-s 
denaturing step at 94”C, a 60-s annealing step at 52°C for bilirubin 
UGT and 55°C for 4-nitrophenol UGT and a 90-s elongation step at 
72°C. Following the final cycle, a 5-min elongation step at 72°C was 
included. 
Fig. 1 shows the glucuronidation activity measured with 
4-nitrophenol (Fig. 1A) and bilirubin (Fig. 1B) as substrates by 
liver microsomes of rats that had been thyroidectomised or 
treated with L-T3, 3-MC or ciprofibrate. Compared to con- 
trols, thyroidectomy significantly reduced by 2-fold the glucu- 
ronidation of 4-nitrophenol, whereas L-T3 or 3-MC admini- 
stration increased the activity by 1.5 or 3-fold, respectively. 
The opposite situation was found for bilirubin glucuronidation, 
as far as the effects of L-T3 are considered; thyroidectomy 
significantly increased the activity; by contrast, administration 
of L-T3 markedly decreased this parameter. On the other hand, 
as expected, treatment with ciprofibrate enhanced the glucu- 
ronidation rate of bilirubin 3-fold. 
The variations in the glucuronidation of 4-nitrophenol and 
bilirubin upon treatment with L-T3 and other inducers were 
strongly related to the expression of the corresponding UGT 
proteins, as revealed by Western blot, using two different anti- 
bodies (Fig. lC,D). The intensity of the 54 kDa band corre- 
sponding to the isoform which glucuronidates bilirubin was 
increased in response to ciprofibrate treatment and thyroid 
ablation (Fig. 1C). On the other hand, an increase in the stain- 
ing of the 4-nitrophenol UGT (56 kDa) was also found in rats 
administered with L-T3 or 3-MC, when compared to control 
or thyroidectomised animals (Fig. 1D). 
Two sets of primers were designed to specifically amplify bilirubin 
and 4-nitrophenol UGTs (Table 1). They were 100% homologous with 
the sequences described by Sato et al. [15] and Iyanagi et al. [16], and 
were chosen in order to avoid any crosslinking with other known 
The proportion of UGT mRNA was estimated from compar- 
ison to that of p-actin mRNA known to be unmodified by 
thyroid [19] and diet conditions [20]. In Fig. 2 is reported the 
analysis of RT-PCR products on polyacrylamide gels: 507 bp 
for the 4-nitrophenol UGT fragment (UGT1*06) and 303 bp 
for the bilirubin UGT fragment (UGTl*O). The specificity of 
the amplification obtained was checked by restriction site anal- 
Table 1 
Synthesized primers used for PCR 
Isoforms Primers 5’3’ sequence Complementary site 
Bilirubin UGT* A GAAGAATATCAGCGGGAAATA 250 to 270 
(UGTI *0) B CGGACATTGTGTAGCCTCA 555 to 537 
4-Nitrophenol UGT** C TTGCCTTCTTCCTGCTGC 6 to 23 
(UGTI *06) D TCTGAAGAGGTAGATGGAAGGC 513 to 492 
/?-Actin*** TGCAGAAGGAGATTACTGCC 2818 to 2837 
CGCAGCTCAGTAACAGTCC 3153 to 3135 
*From rat liver according to the sequence of Sato et al. [15]. 
**From rat liver according to the sequence of Iyanagi et al. [16]. 
***From rat cytoplasmic B-actin gene according to the sequence of Nude1 et al. [17] 
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a new fascinating area of investigation, which is still a pioneer- 
ing work due to lack of specific probes necessary to follow the 
formation of these proteins. This study reports, for the first 
time, the effect of the thyroid hormone L-T3 on the mRNA 
levels of two rat liver UGTs (UGT1*06, UGTl*O). Interest- 
ingly, L-T3 differentially affected the expression of both these 
proteins, by decreasing the glucuronidation of bilirubin, and 
conversely by increasing that of 4-nitrophenol. The absence of 
L-T3 in thyroidectomised animals led to the opposite situation. 
Such results support the hypothesis that L-T3 plays a regula- 
tory role on this enzyme system. The relationship observed 
between enzyme activities and expression of the two UGT 
isoforms as a function of the presence of L-T3 further empha- 
sized the key role played by this hormone. Indeed, in this work, 
thyroidectomy increased bilirubin UGT and decreased 4-nitro- 
phenol UGT mRNA levels concomitantly. The reverse was true 
in hyperthyroid animals. 
The mechanism by which L-T3 modifies the mRNA levels 
encoding UGTl*06 and UGTl*O in opposite way is not 
known, but it is clear that it may depend on a transcriptional 
or post-transcriptional process. Subsequent studies of other 
genes known to be positively regulated by thyroid hormone 
have also demonstrated a significant degree of control at the 
transcriptional level. These genes include the hepatic spot 14, 
the malic enzyme and the rat a-myosin heavy chain gene. Tran- 
scriptional inhibition by thyroid hormone has also been docu- 
mented for the a- and p-subunits of thyroid stimulating 
hormone genes [22 and ref. herein]. Preliminary results by run- 
on analysis obtained in our laboratory suggested a transcrip- 
tional effect of L-T3 toward UGT1*06, eventhough a post 
transcriptional effect could not be ruled out. On the other hand, 
no data are available concerning the regulation of UGTl*O. It 
has been clearly established that UGT1*06 and UGTl*O are 
the result of alternate splicing of specific and common exons 
localised on the same locus [23]. Although encoded by a single 
UGTl gene locus, the expression of the individual UGTl isoen- 
zymes in rats and also possibly in man could be under different 
control mechanisms involving specific nuclear receptors of thy- 
roid hormones (TRs), which are considered as transcriptional 
factors. Moreover it has been found that TRs bind to L-T3 
responsive elements (TREs) as monomers, homodimers or 
heterodimers with other nuclear receptors of the same superfa- 
mily, especially with the retinoid X receptors (RXRs) and the 
xix N LT3 Cipmfib m N L-T3 3-MC 
C D 
_ _ . ~ _ ”  _  
‘IHX L-l-3 N Cipmtib THX LT3 N 3.MC 
Fig. 1. Effect of the thyroid status on the expression of bilirubin UGT 
and 4-nitrophenol UGT in rat liver. The glucuronidation of bilirubin 
(A) and 4-nitrophenol (B) was measured in liver microsomes of thy- 
roidectomised (THX), normal (N), treated with 3,3’,5 triiodo-r-thyro- 
nine (L-T3) or with ciprofibrate (Ciprofib) and 3-methylcholanthrene 
(3-MC). Values are the mean f S.D. of eight animals. *Significantly 
different (P < 0.01) from normal rats. Immunoblot of UGT with (C) 
polyclonal anti-rat liver UGT antibodies which recognize 4-nitrophenol 
UGT (1. 56 kDa). bilirubin UGT (2. 54 kDa). androsterone UGT (3. 
52 kDaj and testosterone UGT (4’50 kDaj;’ with (D) monospecific 
antibodies raised against the human liver UGT1*6, which recognize 
only one UGT which glucuronidates planar phenols including 4-nitro- 
phenol (56 kDa). 
ysis: the 303 bp bilirubin UGT and the 507 bp 4-nitrophenol 
UGT sequences detected in rat liver, once digested with Al& 
EcoRI and HindIII-PvuII, respectively, (lanes 2, 3 and 5, 6) 
gave fragments of the expected size. 
After a first step of reverse transcription allowing the produc- 
tion of cDNA from the different groups of rats, co-amplifica- 
tion of p-actin cDNA and UGT cDNA was performed using 
specific primers (see Table 1). PCR reactions were stopped after 
different amplification cycles and the reaction products were 
separated by electrophoresis on acrylamide gels (Fig. 3A). Log- 
arithms of area intensity were plotted against the number of 
PCR cycles. Straight lines with different slopes were obtained 
as shown in Fig. 3B. The proportion of UGT mRNA to 
/I-actin mRNA was calculated using the formula: A,,,/ 
A,,, = Yu,,( 1 + &.,)“I Y,,,( 1 + RUGT)IZ according to Chelly et al. 
[21], where A is the initial amount of material, R the efficiency, 
n the number of cycles and Y the area intensity; R can be 
deduced from the slope of the semi-log plot: log(1 + R). The 
proportion of bilirubin UGT mRNA to /I-actin mRNA was 
decreased by 54% in rats treated with L-T3, but increased about 
l-fold in thyroidectomised animals (Fig. 4). Treatment with the 
specific inducer ciprofibrate enhanced this content about 2- to 
3-fold. The opposite situation was observed for 4-nitrophenol 
UGT mRNA. Compared to control rats, the levels were in- 
creased 41% in L-T3-treated rats and decreased by 70% in 
thyroidectomised animals. The specific inducer 3-MC increased 
the 4-nitrophenol UGT mRNA more than 3-times (Fig. 4). 
4. Discussion 
The modulation of UGT expression by thyroid hormones is 
Fig. 2. The specificity of the amplification products obtained was mon- 
itored by restriction site analysis. Lanes 1 and 4 show the bilirubin UGT 
(303 bp) and 4-nitrophenol UGT (507 bp) isoforms, respectively; lanes 
2, 3 and lanes 5, 6 show the fragments obtained upon digestion of the 
303 bp product with AM, EcoRI, and of the 507 bp product with 
HindIII, PvuII, respectively. Std lanes refer to DNA molecular weight 
markers (from 24 to 726 bp). 
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A UGTl*O UGTl*O6 
Std 21 23 25 27 28 29 30 32 Std 19 21 23 25 27 28 29 
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UGTl*O UGT 1*06 
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Fig. 3. Kinetic analyses of PCR products from bilirubin UGT (UGTl*O), 4-nitrophenol UGT (UGT1*06) and B-actin mRNAs. Photography of 
acrylamide gel performed on PCR co-amplified products of rats of bilirubin UGT (303 bp), 4-nitrophenol UGT (507 bp) and j%actin (220 bp) gene 
(A). Semi-logarithmic representation of the relative extent of amplification in (B) measured by counting the intensity of the fragments visualized in 
(A): (A) bilirubin UGT; (+) 4-nitrophenol UGT; (0) /I-actin. n is the number of PCR cycles; Y is the intensity of staining. 
peroxisome proliferator-activated receptors (PPARs), and a 
large number of structurally related proteins, termed orphan 
receptors, for which no ligand has yet been identified [24-261. 
THX N L-T3 Ciprofib 3-MC 
Fig. 4. Effects of treatment by L-T3 and specific inducers on hepatic 
bilirubin UGT (light columns) and 4-nitrophenol UGT (dark columns) 
mRNA levels. Each point represents the mean f S.D. of three animals. 
For other details, see legend of Fig. 1. 
On binding their respective ligands, they can activate tran- 
scription, but only at certain binding sites. Elsewhere or with- 
out a ligand, they act as transcriptional repressors, but the 
mechanism responsible is unknown. The diversity provided by 
heterodimerization within the subfamily of nuclear hormone 
receptors offers additional levels of regulation. For example, 
PPAR has been reported to be able to positively or negatively 
modulate TR activity depending on the type of TRE [27]. In 
addition, Thomas Perlmann et al. [28] recently described a new 
transcriptional co-repressor which binds to the receptor for 
thyroid hormone. On binding ligand, however, the DNA- 
bound form undergoes a conformational change which dis- 
places the co-repressor, explaining the effect of the ligand on 
transcription. We think that such interactions could potentially 
have important consequences on the alternate modulation of 
the UGT gene. This hypothesis, which is being investigated in 
our laboratory, could bring further insight in the knowledge of 
the molecular mechanisms of gene regulation of the UGTl 
family by thyroid hormones, retinoic acids and peroxisome 
proliferators. 
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